When was Asieris Pharmaceuticals founded?

Asieris Pharmaceuticals was founded in 2010.

Where is Asieris Pharmaceuticals located?

Asieris Pharmaceuticals is headquartered in Radnor, United States. It is registered at Radnor, Pennsylvania.

Who is the current CEO of Asieris Pharmaceuticals?

Kevin Pan of Asieris Pharmaceuticals. They have also founded 1 company.

How many employees does Asieris Pharmaceuticals have?

As of Apr 30, 2026, the latest employee count at Asieris Pharmaceuticals is 56.

Is Asieris Pharmaceuticals a funded company?

Asieris Pharmaceuticals is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Asieris Pharmaceuticals rank among its competitors?

Asieris Pharmaceuticals ranks 6th amongst 13 active competitors, of which 2 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Lipella, which secured $3.79M in Mar, 2025.

Who are the top competitors of Asieris Pharmaceuticals?

Asieris Pharmaceuticals' top competitors include UroGen Pharma, Lipella and Relmada. Among them, Lipella secured the most recent funding round in March, 2025.

Asieris Pharmaceuticals - 2026 Company Profile, Team & Competitors

Asieris Pharmaceuticals is an unfunded company based in Radnor (United States), founded in 2010 by Kevin Pan. It operates as a Developer of drugs for the treatment of genitourinary tumors and other major diseases. Asieris Pharmaceuticals has not raised any funding yet. The company has 13 active competitors, including 2 funded and 5 that have exited. Its top competitors include companies like UroGen Pharma, Lipella and Relmada.

Company Details

Developer of drugs for the treatment of genitourinary tumors and other major diseases. It offers a pipeline of drug candidates which include APL-1202 an oral methionine aminopeptidase II type inhibitor that inhibits both tumor cell growth and angiogenesis. It also provides APL-1702 cevira which is a photodynamic drug-device combination product that helps in the non-surgical treatment of cervical dysplasia. Other products include APL-1401, and APL-1501 for the treatment of solid tumors.

Website: asieris.com
Email ID: *****@asieris.com
Registered Address: Radnor, Pennsylvania

Key Metrics

Founded Year

2010

Location

Radnor, United States

Stage

Unfunded

Ranked

6^th among 13 active competitors

Employee Count

56 as on Apr 30, 2026

Similar Companies

UroGen Pharma & 15 more

View Asieris Pharmaceuticals' full profile

Asieris Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ASIERIS CIN: 845102958 , United States, Active		-	14 (As on Dec 31, 2024)	-

Asieris Pharmaceuticals has not raised any funding rounds yet.

The founders of Asieris Pharmaceuticals is Kevin Pan.

Here are the details of Asieris Pharmaceuticals' key team members:

Kevin Pan: Founder & CEO of Asieris Pharmaceuticals and founder of 1 other company.
Contact Info: 1 email address

View details of Asieris Pharmaceuticals's Founder profiles and Board Members

Asieris Pharmaceuticals' employee count trend

Asieris Pharmaceuticals has 56 employees as of Apr 26. Here is Asieris Pharmaceuticals's employee count trend over the years:

Employee count trend for Asieris Pharmaceuticals

Uncover Asieris Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Asieris Pharmaceuticals include UroGen Pharma, Lipella and Relmada. Here is the list of Top 10 competitors of Asieris Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	UroGen Pharma 2004, Ra anana (Israel), Public	Developer of therapeutics to treat urothelial and specialty cancers	$7M	Sonostar Ventures, hortoncapital.com & 10 others	64/100
2nd	Lipella 2005, Pittsburgh (United States), Public	Developer of lipid-based therapies for common bladder syndromes	$3.37M	Military Health, HHS	59/100
3rd	Relmada 2007, Blue Bell (United States), Public	Developing innovative therapies for debilitating disorders, improving human health	$13M	BioAdvance, Ben Franklin Technology Partners ... & 1 others	54/100
4th	Prokarium 2012, Keele (United Kingdom), Series C	Developer of microbial immunotherapy platform leveraging bacteria to target and treat cancer	$61.6M	Riyadh Valley Company, Korea Investment Holdings ... & 3 others	53/100
5th	Protara Therapeutics 2017, New York City (United States), Public	Developer of cell therapies to treat lymphatic malfunctions	-	TVM Capital Life Science, Boxer Capital & 8 others	52/100
6th	Asieris Pharmaceuticals 2010, Radnor (United States), Unfunded	Developer of drugs for the treatment of genitourinary tumors and other major diseases	-	-	50/100
7th	Tollys 2015, Lyon (France), Series A	Developer of drugs for treating cancer	$6.97M	Bpifrance	43/100
8th	Rainer Theraputics 2010, San Leandro (United States), Deadpooled	Developer of antibody based therapeutics for bladder cancer	$156M	Sofinnova Investments, Sectoral & 7 others	37/100
9th	Tengion 2004, Audubon (United States), Deadpooled	Regenerative medicine company developing neo-organs & neo-tissues.	$143M	Quaker Partners, RA Capital Management & 14 others	35/100
10th	OncoSTING 2018, Baltimore (United States), Funding Raised	Developer of immunotherapy for bladder cancer	-	HHS	31/100